I det forsøg var incidensen af fatale tromboemboliske hændelser højere hos patienter, som fik epoetin alfa end hos placebogruppen (se afsnit 5. 1).
In that study the incidence of fatal thromboembolic events was higher in patients receiving epoetin alfa than in those receiving placebo (see section 5.1).